Subscribe

Subscribe to Our Newsletter

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks

Industry

Novo Nordisk Acquires Akero Therapeutics for $4.7B, Bolstering Metabolic Disease Pipeline with MASH Treatment post image
M&A Activity pharma-mergers biotech therapeutics

Novo Nordisk Acquires Akero Therapeutics for $4.7B, Bolstering Metabolic Disease Pipeline with MASH Treatment

by Newsdesk
Policy and Funding Headwinds Threaten Boston's Biotech Dominance post image
digital-health pharma-industry Digital Health Industry Trends biotech healthcare-policy healthcare-funding

Policy and Funding Headwinds Threaten Boston's Biotech Dominance

Featured post
by Newsdesk
Novo Nordisk Acquires Akero Therapeutics for $5 Billion to Bolster Liver Disease Pipeline post image
pharma-industry Acquisition M&A Activity pharma-mergers drug-development biotech

Novo Nordisk Acquires Akero Therapeutics for $5 Billion to Bolster Liver Disease Pipeline

Featured post
by Newsdesk
Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion, Bolstering Metabolic and Liver Disease Pipeline post image
Acquisition M&A Activity pharma-mergers biotech drug-development

Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion, Bolstering Metabolic and Liver Disease Pipeline

by Newsdesk
Global Biotech Hubs: Analyzing the Shifting Landscape and Challenges to Boston's Dominance post image
pharma-industry digital-health Industry Trends biotech healthcare-funding healthcare-policy

Global Biotech Hubs: Analyzing the Shifting Landscape and Challenges to Boston's Dominance

Featured post
by Newsdesk
Eli Lilly Commits $1 Billion to Expand India Manufacturing and R&D Capabilities post image
pharma-industry Digital Health Industry Trends pharmaceutical healthcare-funding drug-development

Eli Lilly Commits $1 Billion to Expand India Manufacturing and R&D Capabilities

Featured post
by Newsdesk
NKGen Biotech Clarifies OTC Expert Market Status Amidst Filing Delays, Addresses $0.00 Stock Display post image
Market Analysis biotech regulatory regulatory-compliance

NKGen Biotech Clarifies OTC Expert Market Status Amidst Filing Delays, Addresses $0.00 Stock Display

Featured post
by Newsdesk
India's Pharmaceutical Sector Faces Stricter Compliance Demands Amid Quality Concerns post image
regulatory India Compliance Requirements regulatory-compliance healthcare-policy pharmaceutical

India's Pharmaceutical Sector Faces Stricter Compliance Demands Amid Quality Concerns

by Newsdesk
Costco's Strategic Entry into GLP-1 Market: Implications for Drug Access and Pharmaceutical Retail post image
pharma-industry Market Analysis drug-pricing market-access pharmaceutical

Costco's Strategic Entry into GLP-1 Market: Implications for Drug Access and Pharmaceutical Retail

Featured post
by Newsdesk
Indian Pharmaceutical Alliance Appoints Sharvil Patel Amidst Policy Reforms and Global Expansion Efforts post image
Industry Trends pharmaceutical regulatory industry-trends

Indian Pharmaceutical Alliance Appoints Sharvil Patel Amidst Policy Reforms and Global Expansion Efforts

by Newsdesk
Moscow's BIOCAD Achieves Significant Critical Medicine Production Boost, Supported by City Offset Contracts post image
Market Analysis biotech pharmaceutical healthcare-policy

Moscow's BIOCAD Achieves Significant Critical Medicine Production Boost, Supported by City Offset Contracts

by Newsdesk
Global API Market Projected to Reach $428.5 Billion by 2033, Driven by Biotech & Oncology Amidst Supply Chain Challenges post image
biotech Market Analysis Supply Chain Healthcare Supply Chain pharmaceutical healthcare-market-analysis

Global API Market Projected to Reach $428.5 Billion by 2033, Driven by Biotech & Oncology Amidst Supply Chain Challenges

Featured post
by Newsdesk
Hanmi Pharmaceutical's Encequidar Deal with Gilead Sciences Boosts Shares Amid Global Market Shifts post image
Market Analysis pharmaceutical drug-development market-access

Hanmi Pharmaceutical's Encequidar Deal with Gilead Sciences Boosts Shares Amid Global Market Shifts

by Newsdesk
Factor Bioscience Sues AstraZeneca, Cellectis in High-Stakes Gene-Editing Patent Dispute post image
M&A Activity biotech gene-therapy oncology

Factor Bioscience Sues AstraZeneca, Cellectis in High-Stakes Gene-Editing Patent Dispute

by Newsdesk
US Tariffs on Branded Drugs Spark Significant Decline in Indian Pharma Stocks post image
Market Analysis pharmaceutical healthcare-policy market-access

US Tariffs on Branded Drugs Spark Significant Decline in Indian Pharma Stocks

by Newsdesk